mdCurrent Conference Report: American College of Cardiology’s 61st Annual Scientific Session & Expo A new study looking at an all-oral medication regimen for treating pulmonary embolism (PE) finds it as effective as starting with injectable enoxaparin and then switching to warfarin. The one-agent regimen would permit most of the treatment…
Read more »
mdCurrent Conference Report: International Stroke Conference Warfarin did not reduce the rate of the combined endpoint of death, ischemic stroke, or intracerebral hemorrhage compared with aspirin, according to a Late Breaking Clinical Trial presented at the 2012 International Stroke Conference. Both warfarin and aspirin are used in this clinical setting,…
Read more »
indicates a Peer-Reviewed Article
Apixaban reduces stroke rates in atrial fibrillation patients with previous stroke or TIA
In a subset of patients that had experienced a previous stroke or transient ischemic attack (TIA), treatment with the investigational drug apixaban resulted in a reduced rate of stroke and systemic embolism compared with warfarin, according to a recent subset analysis of a major clinical trial. Stroke is the third-leading…
Read more »